(1)
Renowned Neuroscience Institute in Zurich To Soon Offer Next-Gen Non-Invasive Brain Cancer Treatment
ZAP Surgical Systems, Inc. today announced the imminent installation of its advanced ZAP-X Gyroscopic Radiosurgery platform at the Swiss Neuro Radiosurgery Center (SNRC), an organization within the Swiss Clinical Neuroscience Institute (SCNSI) in Zurich, Switzerland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210513005002/en/
ZAP-X Gyroscopic Radiosurgery Platform (Photo: Business Wire)
Stereotactic radiosurgery (SRS) is a well-studied and effective treatment for many brain cancers including primary and metastatic brain tumors, as well as select intracranial functional and vascular disorders. Considered an alternative to surgery for these indications, SRS is a non-invasive outpatient procedure that often provides equivalent to superior outcomes, yet no surgical incision, and little to no recovery period.
Share this article
Share this article
NAPLES, Fla., May 12, 2021 /PRNewswire/ Enveric Biosciences (NASDAQ: ENVB) ( Enveric or the Company ), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that it has appointed Arash Asher, M.D., Director of Cancer Rehabilitation and Survivorship at the Cedars-Sinai Cancer Center, to the Company s Scientific Advisory Board. We believe that Dr. Asher s decision to join Enveric s Scientific Advisory Board gives the Company a significant advantage given his extensive time and expertise at Cedars-Sinai, said David Johnson, Chairman and CEO, Enveric Biosciences. Our mission at Enveric is focused on improving cancer patients quality of life through leveraging the power of cannabinoid medicines. Dr. Asher s deep knowledge of chemotherapy-induced peripheral neuropathy and more should help us achieve this goal of bringing safe, effective care to can
E-Mail
BOSTON - It s a real-life plot worthy of a classic spy novel: Researchers at Massachusetts General Hospital (MGH), the Dana-Farber Cancer Institute and other Boston-area research centers are turning the tables on glioblastomas, the most devastating and aggressive form of brain cancer, by transforming a type of cell that normally protects tumors and inhibits effective drug therapy into a stone-cold glioblastoma killer.
Glioblastoma, a type of brain tumor, is rapidly fatal: Most patients die within two years of diagnosis despite aggressive therapies such as brain surgery, whole-brain radiation and chemotherapy.
Despite hopes that a class of drugs known as immune checkpoint blockers (ICBs) - drugs that have revolutionized the treatment of patients with malignant melanoma, non-small-cell lung cancer, and other solid tumors - could also benefit patients with glioblastoma, ICBs have not been effective against the disease in clinical trials to date.
By TAPINTO LIVINGSTON STAFF
May 9, 2021 at 2:00 PM
Alan Garten, MD, Interventional Radiologist and Chair of the SBMC Department of Radiology, is elected President of the Saint Barnabas Medical Staff.
Alan Garten, MD, Interventional Radiologist and Chair of the SBMC Department of Radiology, is .
Credits: SBMC
May 9, 2021 at 2:00 PM
LIVINGSTON, NJ The nearly 1,600 attending physicians at Saint Barnabas Medical Center (SBMC) recently elected leaders among the group to serve two-year terms as Medical Staff Officers.
Inducted at the Quarterly Medical Staff Meeting in April were Alan Garten, MD, who will serve as Medical Staff President as well as First Vice President Michael Addis, MD; Second Vice President John Shumko, MD; Secretary Alison Grann, MD; and Treasurer Michael LaSalle, MD.